As an important partner, Teva Respiratory wanted to make you aware of the upcoming launch of QVAR® RediHaler™ (beclomethasone dipropionate HFA) Inhalation Aerosol, which will be available by prescription beginning on February 12, 2018. Teva will be discontinuing QVAR® (beclomethasone dipropionate HFA). Patients and caregivers are encouraged to speak with their doctors to learn more about how this discontinuation may affect their current treatment plans.
Important limitation of use, QVAR® RediHaler™ is not indicated for the relief of acute bronchospasm. QVAR ® RediHaler ™ (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age or older. It contains the same small-particle medication as the currently-available QVAR®, but in a "spacer-free" design (do not use with a spacer). The inhaler no longer requires priming and in addition, it utilizes innovative “breath-actuated” inhaler technology to deliver the medicine, eliminating the need for hand-breath coordination. Prescribing information and additional details: http://hcp.qvar.com/